Article Text

Download PDFPDF
Original research
Bacteria-derived long chain fatty acid exhibits anti-inflammatory properties in colitis
  1. Julien Pujo1,2,
  2. Camille Petitfils1,
  3. Pauline Le Faouder3,
  4. Venessa Eeckhaut4,
  5. Gaelle Payros1,
  6. Sarah Maurel1,
  7. Teresa Perez-Berezo1,
  8. Matthias Van Hul5,
  9. Frederick Barreau1,
  10. Catherine Blanpied1,
  11. Stephane Chavanas6,
  12. Filip Van Immerseel4,
  13. Justine Bertrand-Michel3,
  14. Eric Oswald1,7,
  15. Claude Knauf1,8,
  16. Gilles Dietrich1,
  17. Patrice D Cani5,8,
  18. Nicolas Cenac1
  1. 1IRSD, INSERM, INRA, INP-ENVT, Toulouse University 3 Paul Sabatier, Toulouse, France
  2. 2Farncombe Family Digestive Health Institute, McMaster University Faculty of Health Sciences, Hamilton, Ontario, Canada
  3. 3MetaToulLipidomics Facility, INSERM UMR1048, Toulouse, France
  4. 4Department of Pathology, Bacteriology and Avian Diseases, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium
  5. 5Walloon Excellence in Life Sciences and Biotechnology (WELBIO), Louvain Drug Research Institute, Metabolism and Nutrition Research Group, UCLouvain, Université catholique de Louvain, Brussels, Belgium
  6. 6Centre for Pathophysiology Toulouse-Purpan (CPTP), INSERM, CNRS, University of Toulouse, Toulouse, France
  7. 7Service de bactériologie-hygiène, CHU Toulouse, Hôpital Purpan, Toulouse, France
  8. 8NeuroMicrobiota, European Associated Laboratory (EAL), INSERM/UCLouvain, Toulouse, Brussels, France, Belgium
  1. Correspondence to Dr Nicolas Cenac, UMR1220, IRSD, INSERM, Toulouse, Occitanie, France; nicolas.cenac{at}inserm.fr

Abstract

Objective Data from clinical research suggest that certain probiotic bacterial strains have the potential to modulate colonic inflammation. Nonetheless, these data differ between studies due to the probiotic bacterial strains used and the poor knowledge of their mechanisms of action.

Design By mass-spectrometry, we identified and quantified free long chain fatty acids (LCFAs) in probiotics and assessed the effect of one of them in mouse colitis.

Results Among all the LCFAs quantified by mass spectrometry in Escherichia coli Nissle 1917 (EcN), a probiotic used for the treatment of multiple intestinal disorders, the concentration of 3-hydroxyoctadecaenoic acid (C18-3OH) was increased in EcN compared with other E. coli strains tested. Oral administration of C18-3OH decreased colitis induced by dextran sulfate sodium in mice. To determine whether other bacteria composing the microbiota are able to produce C18-3OH, we targeted the gut microbiota of mice with prebiotic fructooligosaccharides (FOS). The anti-inflammatory properties of FOS were associated with an increase in colonic C18-3OH concentration. Microbiota analyses revealed that the concentration of C18-3OH was correlated with an increase in the abundance in Allobaculum, Holdemanella and Parabacteroides. In culture, Holdemanella biformis produced high concentration of C18-3OH. Finally, using TR-FRET binding assay and gene expression analysis, we demonstrated that the C18-3OH is an agonist of peroxisome proliferator activated receptor gamma.

Conclusion The production of C18-3OH by bacteria could be one of the mechanisms implicated in the anti-inflammatory properties of probiotics. The production of LCFA-3OH by bacteria could be implicated in the microbiota/host interactions.

  • enteric bacterial microflora
  • probiotics
  • lipids
  • experimental colitis
  • PPAR gamma
View Full Text

Statistics from Altmetric.com

Footnotes

  • JP and CP are joint first authors.

  • Twitter @MicrObesity

  • Contributors JLFP and CP designed and conducted experiments, performed data acquisition, analysis and interpretation, and wrote the manuscript. PLF designed and conducted experiments, performed data acquisition, analysis and interpretation and drafting of the manuscript. VE, GP, SM, TP-B, MVH, FB and CB carried out experiments, performed data acquisition, analysis. SC and FVI conducted experiments and contributed with the drafting of the manuscript. JB-M and EO contributed to data analysis and interpretation and edition of the manuscript. GD participated in the manuscript writing. PDC designed experiments, performed interpretation of data, helped with manuscript drafting and supervised microbiota study. NC designed and conducted experiments, performed analysis and interpretation of data, wrote the manuscript and directed the project.

  • Funding NC is a recipient of the grant from ANR (ANR-18-CE14-0039-01). PDC is a senior research associate at FRS-FNRS (Fonds de la Recherche Scientifique) and recipient of grants from FNRS (WELBIO-CR-2019C-02R, 'The Excellence Of Science: EOS 30770923') and the Funds Baillet Latour (Grant for Medical Research 2015). CK is a recipient of the grant from ANR (ENDIABAC, ANR-18-CE14-0007-01).

  • Competing interests None declared.

  • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

  • Patient consent for publication Not required.

  • Ethics approval All procedures were performed in accordance with the Guide for the Care and Use of Laboratory Animals of the European Council and were approved by the Animal Care and Ethics Committee of US006/CREFE (CEEA-122; application number APAFIS #7762-CE2016112509278235V2).

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data availability statement All data relevant to the study are included in the article or uploaded as supplementary information.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.